Watson Receives FDA Approval for Generic Percocet(R) 7.5mg/325mg and 10mg/325mg
- Will Represent Watson's 12th Generic Product Launch in 2003 -
CORONA, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for Oxycodone and Acetaminophen (APAP) tablets in 7.5mg/325mg and 10mg/325mg strengths. Oxycodone/APAP is the generic equivalent to Endo Pharmaceuticals' Percocet(R) tablets and is indicated for the relief of moderate to moderately severe pain. For the 12-months ending June 2003, Percocet(R) 7.5mg/325mg and 10mg/325mg had sales of approximately $142 million. (Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO ) The Company expects a full launch by late 2003 and timing is dependent on obtaining quota from the Drug Enforcement Administration, adequate supply of active ingredient, and build-up of launch quantities. About Watson Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com . Forward-Looking Statement Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2002 and its Quarterly Report on Form 10-Q for the quarters ended March 31 and June 30, 2003. Percocet(R) is a registered trademark of Endo Pharmaceuticals, Inc.
SOURCE Watson Pharmaceuticals, Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.